Drugs / BI 705564
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03747926 | Apr → Aug 2019 | — | Boehringer Ingelheim | Withdrawn | No outcome recorded |
| Phase 1 | NCT03771885 | Mar → Dec 2019 | systemic lupus erythematosus | Boehringer Ingelheim | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT03325712 | Nov 2017 → Nov 2018 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03123185 | Apr 2017 → Feb 2018 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 705564 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03123185 ↗ |
| Route | Oral | “BI 705564 in healthy male subjects following oral administration of single rising doses” NCT03123185 ↗ |